GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Audeo Oncology Inc (DELISTED:AURX) » Definitions » EPS without NRI

Audeo Oncology (Audeo Oncology) EPS without NRI : $0.00 (TTM As of Sep. 2012)


View and export this data going back to . Start your Free Trial

What is Audeo Oncology EPS without NRI?

Audeo Oncology's earnings per share without non-recurring items for the three months ended in Sep. 2012 was $0.00. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2012 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Audeo Oncology's EPS without NRI or its related term are showing as below:

AURX's 3-Year EPS without NRI Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 10.6
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Audeo Oncology's EPS (Diluted) for the three months ended in Sep. 2012 was $0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2012 was $0.00.

Audeo Oncology's EPS (Basic) for the three months ended in Sep. 2012 was $0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2012 was $0.00.


Audeo Oncology EPS without NRI Historical Data

The historical data trend for Audeo Oncology's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Audeo Oncology EPS without NRI Chart

Audeo Oncology Annual Data
Trend Jun10 Jun11 Jun12
EPS without NRI
- - -

Audeo Oncology Quarterly Data
Jun11 Mar12 Jun12 Sep12
EPS without NRI - - - -

Competitive Comparison of Audeo Oncology's EPS without NRI

For the Drug Manufacturers - General subindustry, Audeo Oncology's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Audeo Oncology's PE Ratio without NRI Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Audeo Oncology's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Audeo Oncology's PE Ratio without NRI falls into.



Audeo Oncology EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2012 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Audeo Oncology  (DELISTED:AURX) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Audeo Oncology EPS without NRI Related Terms

Thank you for viewing the detailed overview of Audeo Oncology's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Audeo Oncology (Audeo Oncology) Business Description

Traded in Other Exchanges
N/A
Address
Audeo Oncology, Inc was incorporated in Delaware in June 2012. It is a late stage biopharmaceutical company utilizing its Hyaluronic Acid Chemotransport Technology, or HyACT, to target cancer drugs preferentially to tumor cells to enhance drug activity. HyACT is a flexible platform technology designed to increase the effectiveness of anti-cancer agents without increasing treatment toxicity. It seeks to reduce the risks related to drug development by using known anti-cancer drugs, and aim to enhance their commercial value by improving their effectiveness. The Company's lead HyACT product candidate, HA-Irinotecan, is currently in a pivotal Phase III clinical trial for metastatic colorectal cancer, or mCRC. HA-Irinotecan is also in an investigator-sponsored Phase II clinical trial for small cell lung cancer, or SCLC. It also has two other HyACT product candidates that have successfully completed Phase I clinical trials. In addition to its current clinical-stage product candidates, it aims to develop a pipeline of product candidates by exploiting its significant know-how in cancer stem cell biology and cancer metabolism combined with the Versatile Assembly on Stable Templates, or VAST, molecule drug discovery technology that it will in-license. The Company's lead product candidate is HyACT-targeted irinotecan, or HA-Irinotecan, for the treatment of mCRC. Irinotecan, which is marketed in major markets by Pfizer as Camptosar, is an off-patent chemotherapy drug widely used in the treatment of mCRC. Government authorities in the United States (including federal, state and local authorities) and in other countries extensively regulate the manufacture, research, clinical development, labeling, packaging, distribution, post-approval monitoring and reporting, advertising, promotion, export and import of pharmaceutical products, such as those it is developing.